Bio-Techne Corporation Announces Strategic Partnership with Spear Bio to Advance Biomarker Detection in Neurodegenerative Disease Research

Reuters

2025/07/15

Bio-<a href="https://laohu8.com/S/TECH">Techne Corporation</a> Announces Strategic Partnership with Spear Bio to Advance Biomarker Detection in Neurodegenerative Disease Research

Bio-Techne Corporation has announced a strategic partnership with Spear Bio to distribute their next-generation ultrasensitive immunoassays. This collaboration will enable the detection of low-abundance biomarkers in neurology, focusing particularly on Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and phosphorylated tau 231 (pTau 231). By combining Bio-Techne's extensive distribution network with Spear Bio's advanced immunoassay technology, researchers worldwide will be better equipped to investigate early disease mechanisms and improve patient stratification in clinical trials. This partnership follows Bio-Techne's involvement in Spear Bio's $45 million Series A funding round, emphasizing their joint commitment to advancing biomarker detection and accelerating therapeutic development in neurodegenerative diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG28398) on July 15, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2551376161"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551376161\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551376161?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551376161","market":"nz","top_or_hot":-1,"title":"Bio-Techne Corporation Announces Strategic Partnership with Spear Bio to Advance Biomarker Detection in Neurodegenerative Disease Research","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bio-<a href=\"https://laohu8.com/S/TECH\">Techne Corporation</a> Announces Strategic Partnership with Spear Bio to Advance Biomarker Detection in Neurodegenerative Disease Research\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bio-Techne Corporation has announced a strategic partnership with Spear Bio to distribute their next-generation ultrasensitive immunoassays. This collaboration will enable the detection of low-abundance biomarkers in neurology, focusing particularly on Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and phosphorylated tau 231 (pTau 231). By combining Bio-Techne's extensive distribution network with Spear Bio's advanced immunoassay technology, researchers worldwide will be better equipped to investigate early disease mechanisms and improve patient stratification in clinical trials. This partnership follows Bio-Techne's involvement in Spear Bio's $45 million Series A funding round, emphasizing their joint commitment to advancing biomarker detection and accelerating therapeutic development in neurodegenerative diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG28398) on July 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Techne Corporation Announces Strategic Partnership with Spear Bio to Advance Biomarker Detection in Neurodegenerative Disease Research</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Techne Corporation Announces Strategic Partnership with Spear Bio to Advance Biomarker Detection in Neurodegenerative Disease Research\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-15 19:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bio-<a href=\"https://laohu8.com/S/TECH\">Techne Corporation</a> Announces Strategic Partnership with Spear Bio to Advance Biomarker Detection in Neurodegenerative Disease Research\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bio-Techne Corporation has announced a strategic partnership with Spear Bio to distribute their next-generation ultrasensitive immunoassays. This collaboration will enable the detection of low-abundance biomarkers in neurology, focusing particularly on Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and phosphorylated tau 231 (pTau 231). By combining Bio-Techne's extensive distribution network with Spear Bio's advanced immunoassay technology, researchers worldwide will be better equipped to investigate early disease mechanisms and improve patient stratification in clinical trials. This partnership follows Bio-Techne's involvement in Spear Bio's $45 million Series A funding round, emphasizing their joint commitment to advancing biomarker detection and accelerating therapeutic development in neurodegenerative diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG28398) on July 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0034390439.USD","symbol_name":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nNDL1dSHf4:1","article_id":"2551376161","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551376161","pubTimestamp":1752577280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Bio-Techne Corporation Announces Strategic Partnership with Spear Bio to Advance Biomarker Detection in Neurodegenerative Disease Research. Bio-Techne Corporation has announced a strategic partnership with Spear Bio to distribute their next-generation ultrasensitive immunoassays. This collaboration will enable the detection of low-abundance biomarkers in neurology, focusing particularly on Alzheimer's disease biomarkers such as phosphorylated tau 217 , GFAP, neurofilament light , and phosphorylated tau 231 . By combining Bio-Techne's extensive distribution network with Spear Bio's advanced immunoassay technology, researchers worldwide will be better equipped to investigate early disease mechanisms and improve patient stratification in clinical trials. This partnership follows Bio-Techne's involvement in Spear Bio's $45 million Series A funding round, emphasizing their joint commitment to advancing biomarker detection and accelerating therapeutic development in neurodegenerative disease","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","TECH":"Techne Corporation","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","BK4121":"生命科学工具和服务"},"translate_title":"Bio-Techne Corporation宣布与Spear Bio建立战略合作伙伴关系，推进神经退行性疾病研究中的生物标志物检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":0.9},"content_text":"Bio-Techne Corporation Announces Strategic Partnership with Spear Bio to Advance Biomarker Detection in Neurodegenerative Disease Research\n    \n\n        Bio-Techne Corporation has announced a strategic partnership with Spear Bio to distribute their next-generation ultrasensitive immunoassays. This collaboration will enable the detection of low-abundance biomarkers in neurology, focusing particularly on Alzheimer's disease biomarkers such as phosphorylated tau 217 (pTau 217), GFAP, neurofilament light (Nf-L), and phosphorylated tau 231 (pTau 231). By combining Bio-Techne's extensive distribution network with Spear Bio's advanced immunoassay technology, researchers worldwide will be better equipped to investigate early disease mechanisms and improve patient stratification in clinical trials. This partnership follows Bio-Techne's involvement in Spear Bio's $45 million Series A funding round, emphasizing their joint commitment to advancing biomarker detection and accelerating therapeutic development in neurodegenerative diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Techne Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CG28398) on July 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}